BLIS Technologies Ltd. engages in the development of healthcare products based on strains of bacteria that produce bacteriocin activity. It operates in the following geographical areas: Asia Pacific, Europe Middle East and Africa (EMEA), and North America. The company was founded by John R. Tagg in 2000 and is headquartered in Dunedin, New Zealand.